Glenmark Pharmaceuticals gained 0.92% to Rs 520.80 after the company received tentative ANDA approval for Dabigatran Etexilate Capsules.
The drug company before market hours today announced that it received tentative approval by the USFDA for Dabigatran Etexilate Capsules, 75 mg, 110 mg, and 150 mg. The capsules are generic version of Pradaxa Capsules, 75 mg, 110 mg, and 150 mg, of Boehringer Ingelheim Pharmaceuticals, Inc.
According to IQVIA sales data for the 12 month period ending October 2020, the Pradaxa Capsules, achieved annual sales of approximately $550.9 million.
Glenmark s current portfolio consists of 166 products authorized for distribution in the U.S. marketplace and 45 ANDA s pending approval with the USFDA.
Glenmark Pharmaceuticals is a global research-led pharmaceutical company with presence across generics, specialty and over-the-counter (OTC) business with operations in over 50 countries. Glenmark s key therapy focus areas globally are respiratory, dermatolo
The equity barometers extended losses and hit the day s low in afternoon trade. At 13:20 IST, the barometer index, the S&P BSE Sensex, fell 316.41 points or 0.67% at 46,644.28. The Nifty 50 index slipped 96.55 points or 0.70% at 13,664.
The selling was broad based. The S&P BSE Mid-Cap index fell 0.87%. The S&P BSE Small-Cap index lost 0.73%.
Sellers outnumbered buyers. On the BSE, 1,085 shares rose and 1,779 shares fell. A total of 155 shares were unchanged. In Nifty 50 index, 13 stocks advanced while 37 stocks declined.
Foreign portfolio investors (FPIs) bought shares worth Rs 2,720.95 crore, while domestic institutional investors (DIIs), were net sellers to the tune of Rs 2,424.61 crore in the Indian equity market on 18 December 2020, provisional data showed.
Glenmark Pharmaceuticals receives ANDA tentative approval bignewsnetwork.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from bignewsnetwork.com Daily Mail and Mail on Sunday newspapers.
Glenmark Pharmaceuticals Ltd
Glenmark Pharmaceuticals receives ANDA tentative approval for Dabigatran Etexilate Capsules, 75 mg, 110 mg, and 150 mg ANI | Updated: Dec 21, 2020 11:54 IST
Mumbai (Maharashtra) [India], December 21 (ANI/PRNewswire): Glenmark Pharmaceuticals Ltd (Glenmark) has received tentative approval by the United States Food & Drug Administration (U.S. FDA) for Dabigatran Etexilate Capsules, 75 mg, 110 mg, and 150 mg, the generic version of Pradaxa®1 Capsules, 75 mg, 110 mg, and 150 mg, of Boehringer Ingelheim Pharmaceuticals, Inc.
According to IQVIATM sales data for the 12 month period ending October 2020, the Pradaxa® Capsules, 75 mg, 110 mg, and 150 mg market2 achieved annual sales of approximately USD 550.9 million.
Glenmark s current portfolio consists of 166 products authorized for distribution in the U.S. marketplace and 45 ANDA s pending approval with the US FDA. In addition to these internal filings, Glenmark con
Key equity indices corrected sharply on Monday, tracking weak global cues. All sectoral indices on the NSE ended in the red. PSU stocks, banks and metal shares witnessed major selling.
As per provisional closing data, the barometer index, the S&P BSE Sensex, lost 1406.73 points or 3% to 45,553.96. The Nifty 50 index slumped 432.15 points or 3.14% at 13,328.55.
Investors locked profits after the Sensex added 2.18% and the Nifty gained 2.09% in the past six consecutive sessions. The imposition of fresh lockdown restrictions in several European countries as well as growing risks of a no-deal Brexit after the deadline ends on 31 December 2020 dampened global risk appetite.